Suchergebnisse - "Collongues, Nicolas"

PubPharm (7)

1

Anti-CD20 immunotherapy in progressive multiple sclerosis : 2-year real-world follow-up of 108 patients

enthalten in: Journal of neurology | 2022

von Einsiedler, M. | Kremer, L. | Fleury, M. | +3

2

Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis : an observational study

enthalten in: Journal of neurology | 2022

von Bigaut, K. | Kremer, L. | Fabacher, T. | +7

3

Long-term effect of natalizumab in patients with RRMS : TYSTEN cohort

enthalten in: Multiple sclerosis (Houndmills, Basingstoke, England) | 2021

von Bigaut, K. | Fabacher, T. | Kremer, L. | +10

4

Delay from treatment start to full effect of immunotherapies for multiple sclerosis

enthalten in: Brain : a journal of neurology | 2020

von Roos, I. | Leray, E. | Frascoli, F. | +142

5

Ocrelizumab for the treatment of multiple sclerosis

enthalten in: Expert review of neurotherapeutics | 2019

von Bigaut, K. | De Seze, J. | Collongues, N.

6

CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy

enthalten in: Neurology | 2016

von Pignolet, B. | Schwab, N. | Schneider-Hohendorf, T. | +133

7

Comparative efficacy of fingolimod vs natalizumab : A French multicenter observational study

enthalten in: Neurology | 2016

von Barbin, L. | Rousseau, C. | Jousset, N. | +132

CommentIn: Neurology. 2016 Sep 6;87(10):1065-6. - PMID 27597556

1
[1]